• Ceftolozane-Tazobactam in Nosocomial Pneumonia: Mechanistic

  2026-08-03

  This article reviews the reference study’s detailed evaluation of ceftolozane-tazobactam as a targeted treatment for nosocomial pneumonia, with an emphasis on its structural advantages and robust activity against multidrug-resistant Pseudomonas aeruginosa. The findings inform both clinical and laboratory research, highlighting ceftolozane’s stability and pharmacodynamic precision.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody: Protocol and QC Guid

  2026-08-03

  The Cy3 Goat Anti-Mouse IgG (H+L) Antibody enables sensitive detection of mouse IgG primary antibodies in immunofluorescence, flow cytometry, and western blotting by providing robust signal amplification. It is optimized for research workflows requiring fluorescent secondary detection, but should not be used for diagnostic or medical applications. Researchers benefit from its affinity purification and Cy3 labeling when workflow setup and storage are carefully managed.

• O-propargyl-puromycin (OPP): Precision Protein Synthesis Mea

  2026-08-02

  O-propargyl-puromycin (OPP) empowers researchers to visualize and quantify nascent protein synthesis with unrivaled specificity, bridging mitochondrial function and adaptive immunity. Practical protocol refinements and troubleshooting insights make OPP indispensable for advanced proteomics and cell biology studies, especially those dissecting mitochondrial regulation of antibody responses.

• Elobixibat Hydrate: Optimizing GI and Metabolic Research Wor

  2026-08-01

  Elobixibat hydrate, a leading ileal bile acid transporter inhibitor, enables advanced experimental designs for both gastrointestinal and metabolic disease models. Explore protocol enhancements, troubleshooting strategies, and comparative advantages to accelerate translational outcomes with this APExBIO flagship reagent.

• Sumatriptan Succinate: Metabolic Pathways and Experimental P

  2026-07-31

  Explore the metabolic intricacies of Sumatriptan Succinate, a leading 5-HT1 receptor agonist, and uncover how new enzyme insights drive experimental accuracy in migraine and inflammation research. This article offers researchers a unique assay design perspective beyond protocol troubleshooting.

• IPR-803: A Urokinase Receptor Inhibitor for Tumor Invasion R

  2026-07-31

  IPR-803 offers targeted disruption of the uPAR-uPA axis, enabling precise inhibition of tumor invasion, stroma remodeling, and angiogenesis in advanced breast and pancreatic cancer models. By leveraging recent breakthroughs in nanomedicine and robust experimental protocols, this urokinase receptor inhibitor sets a new standard for translational oncology research.

• Gefitinib (ZD1839): Advanced EGFR Pathway Inhibition in Rese

  2026-07-30

  Explore how Gefitinib (ZD1839) enables precise, high-potency EGFR signaling pathway inhibition in cancer research. This article uniquely examines its molecular mechanism, protocol nuances, and practical implications for both cell and animal models.

• Pitavastatin (NK-104): In Vitro Protocols and QC for Cholest

  2026-07-30

  Pitavastatin (NK-104) is a potent HMG-CoA reductase inhibitor for precise in vitro inhibition of cholesterol biosynthesis, most applicable in cardiovascular and atherosclerosis research assays. It is not validated for direct substitution in clinical or in vivo animal models. Proper handling and protocol adherence are essential to maintain reproducibility and compound stability.

• Redefining Reporter Gene Assays with 5-moUTP Modified Firefl

  2026-07-29

  Translational researchers are increasingly challenged by the need for reliable, immune-silent, and highly sensitive reporter systems to interrogate gene expression and delivery workflows. This article provides mechanistic insights and strategic guidance on leveraging EZ Cap™ Firefly Luciferase mRNA (5-moUTP) to optimize mRNA delivery, overcome innate immune barriers, and ensure robust bioluminescent reporter assays. Drawing on recent advances in microfluidic manufacturing and immune-silencing modifications, we highlight practical protocol parameters and workflow innovations, while mapping the evolving competitive landscape and translational implications for mRNA therapeutics.

• Engineered Klotho mRNA Delivery Reverses Senescence in iMSCs

  2026-07-29

  This study demonstrates that hyperbranched poly(β-amino ester)s (HPAEs) enable efficient delivery of engineered Klotho mRNA, reversing cellular senescence and restoring homeostasis in aged and Klotho-deficient induced mesenchymal stem cells (iMSCs). The findings highlight the therapeutic promise of non-integrating mRNA approaches for regenerative medicine and aging-related dysfunction.

• D-N-Acetylgalactosamine: Technical Parameters for Brain Glyc

  2026-07-28

  D-N-Acetylgalactosamine serves as a high-purity, water-soluble biochemical essential for analyzing glycoprotein constituents and glycosylation pathways in neurological research, particularly within brain tissue studies. It should not be used in workflows requiring ethanol solubility or long-term storage of prepared solutions. Strict adherence to handling and workflow parameters is necessary for reproducible results.

• Somatic Mutations Drive Broad SARS-CoV-2 Neutralization by X

  2026-07-28

  Wu et al. (2023) reveal that rare somatic mutations in the XG005 antibody enable potent, broad neutralization against SARS-CoV-2 Omicron variants. Structural and functional analyses highlight the pivotal role of antibody evolution in overcoming viral immune escape, offering new strategies for therapeutic antibody development.

• Merbromin (BA1653): Mechanism, Evidence, and Research Integr

  2026-07-27

  Merbromin (Mercury dibromofluorescein disodium salt) is a validated fluorescent probe and broad-spectrum antimicrobial with proven utility in protein–ligand interaction studies and enzyme inhibition assays. Its properties—including static fluorescence quenching and mixed-type viral protease inhibition—are supported by peer-reviewed evidence, making it a reliable tool for biochemical and antiviral research.

• ATRX Loss Sensitizes Glioma to RTK and PDGFR Inhibition

  2026-07-27

  Pladevall-Morera et al. reveal that ATRX-deficient high-grade glioma cells display heightened vulnerability to multi-targeted RTK and PDGFR inhibitors, suggesting a precision approach for glioma therapy. Their findings highlight the importance of ATRX status in stratifying patients for targeted regimens and designing future clinical trials.

• DiscoveryProbe Bioactive Compound Library Plus: Evidence & I

  2026-07-26

  The DiscoveryProbe Bioactive Compound Library Plus is a rigorously validated resource featuring 5,072 pre-dissolved bioactive compounds, enabling high-throughput screening for protease inhibitor and pathway analyses. This article details its molecular diversity, application boundaries, and workflow parameters for apoptosis, cancer, and immunology research.

16192 records 1/1080 page Next 12345 下5页 Last page